Latest News & Features
Big Pharma
The products made by GQ Life Sciences, based in Boston, make IP-related sequence searching easier for scientists, patent searchers and practitioners, as senior product manager Ellen Sherin tells LSIPR. 8 July 2017
Europe
The English High Court is seeking answers from the CJEU on aspects of the EU’s regulation on supplementary protection certificates, but it’s possible questions will remain following the rulings. Michael Pears and Joel Beevers of Potter Clarkson report. 5 July 2017
Medtech
Now that Costa Rica has allowed adult stem cells to be used as part of regenerative therapies, the country should be able to attract more investment, say María del Pilar López and Esteban Monge of Zürcher Lawyers. 4 July 2017
Genetics
Despite their great ability to fight diseases, gene therapies face tough challenges from an IP and regulatory perspective in Mexico, as Hector Chagoya and Mariana Gonzalez of Becerril, Coca & Becerril report. 3 July 2017
Europe
Almost one year after the US Supreme Court’s Halo decision, companies should consider a handful of best practices to reduce the risk of paying enhanced damages for wilful patent infringement, as Lynde Herzbach of Birch Stewart Kolasch Birch reports. 30 June 2017
Biotechnology
An advice system for labelling products in Mexico has been extended to food and non-alcoholic beverages. Daniel Sanchez and Victor Ramirez of Olivares report on how the regime works in practice. 30 June 2017
Genetics
Marisa Moura Momoli of Di Blasi, Parente & Associados looks at the fast-developing CRISPR/Cas9 technology and discusses its patentability in Brazil. 29 June 2017
article
Two decisions in India on the protection of plant varieties provide useful guidance in this area, as Archana Shanker of Anand and Anand reports. 29 June 2017
Europe
Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co. 28 June 2017
Biotechnology
The formal requirements for priority have become a hot topic at the European Patent Office, driven by their importance in high-profile oppositions to the Broad Institute’s CRISPR/Cas9 patents, as Catherine Coombes of HGF explains. 28 June 2017